Single nucleotide polymorphisms to predict taxanes toxicities and effectiveness in cancer patients

Sara Demurtas, Nicla La Verde, Selene Rota, Giovanni Casazza, Cristina Montrasio, Stefania Cheli, Maria Silvia Cona, Davide Dalu, Cinzia Fasola, Sabrina Ferrario, Virginio Filipazzi, Anna Gambaro, Nicoletta Tosca, Emilio Clementi

Research output: Contribution to journalArticlepeer-review

Abstract

Taxanes are used in the treatment of several solid tumours. Adverse events (AEs) might be influenced by single nucleotide polymorphisms (SNPs) in genes encoding proteins responsible for pharmacokinetic and pharmacodynamic. In this prospective, monocentric, observational study we explored the effect of SNPs in the main genes involved in taxanes metabolism and transport, on toxicity and efficacy in 125 patients (pts) treated with paclitaxel, nab-paclitaxel, or docetaxel for neoplasms. There was no statistically significant association between the investigated SNPs and AEs. The heterozygous genotype of CYP3A4*22 showed a trend of association with skin reactions in pts treated with paclitaxel and nab-paclitaxel (RR = 6.92; 95% CI 0.47, 99.8; p = 0.0766). CYP2C8*3/*4 variant carriers showed a trend of association with overall AEs in pts treated with paclitaxel and nab-paclitaxel (RR = 1.28; 95% CI 0.96, 1.67; p = 0.0898). No statistically significant relationship with treatment efficacy was found. ABCB1 3435TT showed a trend of association with a higher treatment response (RR = 0.22; 95% CI 0.03, 1.51; p = 0.0876). Despite the population was heterogeneous, CYP3A4*22 and CYP2C8 SNPs may influence paclitaxel and nab-paclitaxel toxicity and ABCB1 c.3435 may affect taxanes effectiveness, even if any statistically significant was found.

Original languageEnglish
JournalPharmacogenomics Journal
DOIs
Publication statusAccepted/In press - 2021

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology

Fingerprint Dive into the research topics of 'Single nucleotide polymorphisms to predict taxanes toxicities and effectiveness in cancer patients'. Together they form a unique fingerprint.

Cite this